AI-designed drug rentosertib lowers aging-clock scores in small IPF trial
A Nature Biotechnology analysis ran six proteomic aging clocks on blood from a 12-week rentosertib trial in lung fibrosis. All six read younger in treated patients, but the design cannot separate aging from disease.
